Clinical Trial Update: Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating rapcabtagene autoleucel for severe active granulomatosis with polyangiitis and microscopic polyangiitis (ANCA-associated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• Rapcabtagene Autoleucel

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: ANCA Associated Vasculitis (AAV) | Phase 2 | Status: RECRUITING